Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases

Clinical and Experimental Immunology

Volumn 107, Issue 1, 1997, Pages 89-95

  Jodo, S ^a   Kobayashi, S ^b   Kayagaki, N ^c   Ogura, N ^a   Feng, Y ^a   Amasaki, Y ^a   Fujisaku, A ^a   Azuma, M ^c   Yagita, H ^c   Okumura, K ^c   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Alternative splicing; Disease activity; Soluble Fas; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; FAS ANTIGEN; PREDNISOLONE;

ADULT; ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSIS; DISEASE ACTIVITY; DRUG THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETIOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 8044251511     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.d01-901.x     Document Type: Article

References (44)

1. Mountz JD, Wu J. Cheng J et al. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415-20.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
3. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-56.
4. Trauth BC, Klas C, Peters AMJ et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-5.
5. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43.
6. Oehm A, Behrmann I, Falk W et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 1992; 267: 10709-15.
7. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994; 57: 129-44.
8. Watanabe-Fukunaga R, Brannan CL, Itoh N et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274-9.
9. Takahashi T, Tanaka M, Brannan CL et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-76.
10. Watanabe-Fukunaga R, Brannan CL, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-7.
11. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 1993; 90: 1756-60.
12. Kobayashi S, Hirano T, Kakinuma M et al. Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice. Biochem Biophys Res Commun 1993; 191: 617-24.
13. Wu J, Zhou T, He J et al. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 1993; 178: 461-8.
14. Chu J-L, Drappa J, Parnassa A et al. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 1993; 178: 723-30.
15. Russell JH, Rush B, Weaver C et al. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 1993; 90: 4409-13.
16. Russell JH, Wang R. Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells. Eur J Immunol 1993; 23: 2379-82.
17. Mysler E, Bini P, Drappa J et al. The Apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994; 93: 1029-34.
18. Ohsako S, Hara M, Harigai M et al. Expression and function of Fas antigen and bel-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994; 73: 109-14.
19. Amasaki Y, Kobayashi S, Takeda T et al. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Fxp Immunol 1995; 99: 245-50.
20. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
21. Knipping E, Krummer PH, Onel KB et al. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38: 1735-7.
22. Goel N, Ulrich DT, St Clair EW et al. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995; 38: 1738-43.
23. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
24. Arnett FC, Edworthy SM, Block DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. Masi AT, Rodnan GP, Medsger TA Jr et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
26. Bohan A, Pete JB, Bowman RL et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56: 255-86.
27. Homma M, Tojo T. Akizuki M et al. Criteria for Sjögren's syndrome in Japan. Scand J Rheumatol 1986; 61 (Suppl.): 26-27.
28. Bombardiere C, Gladmann DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
29. McLaughlin JR, Bombardier C, Farewell VT et al. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994; 37: 559-67.
30. Cifone MG, DeMaria R, Roncaioli P et al. Apoptotic signalling through CD95 (Fas/APO-1) activates an acidic sphingomyelinase. J Exp Med 1994; 180: 1547-52.
31. Yonehara S, Nishimura Y, Kishi S et al. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int Immunol 1994; 6: 1849-56.
32. Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777-83.
33. Cascino I, Fiueci G, Papoff G et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706-13.
34. Nophar Y, Kemper O, Brakebush C et al. Soluble forms of tumour necrosis factor receptors (TNF-Rs): the cDNA for the type 1 TNF-R, cloned both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269-78.
35. Rubin LA, Kurman CC, Fritz ME et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135 3172-7.
36. Suda T, Okazaki T, Naito Y et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806-13.
37. Debatin K-M, Suss D, Krammer PH. Differential expression of APO-1 on human thymocytes: implications for negative selection? Eur J Immunol 1994; 24: 753-8.
38. 2+-independent T cell-mediated cytotoxicily. J Exp Med 1993; 177: 195-200.
39. Dhein J, Walczak H, Baumler C et al. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995; 373: 438-41.
40. Brunner T, Mogil RJ, LaFace D et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-4.
41. Ju S-T, Panka DJ, Cui H et al. Fas (CD95) FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-8.
42. Rieux-Laucat F, Le Deist F, Hivroz C et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-9.
43. Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-46.
44. Hanabuchi S, Koyanagi M, Kawasaki A et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994; 91: 4930-4.